Warning Letters Special Report: Why Investigations Once Again Led Drug GMP Problem Areas In 2022 And What To Do About It

In this fourth installment of our in-depth series, the Pink Sheet reports that inadequate investigations topped the list of problem areas cited in US FDA 2022 drug GMP warning letters. Experts share key pointers on investigating complaints, OOS results, nonconformances and deviations.

2022 Warning Letters Special Report
many poor investigations and a few better practices • Source: Shutterstock

More from Manufacturing

More from Compliance